Voriconazole
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Voriconazole |
| DrugBank ID | DB00582 |
| Brand Names (EU) | Voriconazole Accord |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.29% |
Approved Indication (EMA)
Voriconazole is a broad-spectrum, triazole antifungal agent and is indicated in adults and children aged two years and above as follows: treatment of invasive aspergillosis; treatment of candidaemia in non-neutropenic patients; treatment of fluconazole-resistant serious invasive Candida infections (including C. krusei); Treatment of serious fungal infections caused by Scedosporium spp. and Fusarium spp. Voriconazole Accord should be administered primarily to patients with progressive, possibly
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | fusariosis | 99.29% | DL |
| 2 | multidrug-resistant tuberculosis | 98.67% | DL |
| 3 | cysticercosis | 98.34% | DL |
| 4 | Ambras type hypertrichosis universalis congenita | 98.28% | DL |
| 5 | syndrome with a Dandy-Walker malformation as major feature | 98.15% | DL |
| 6 | malformation syndrome with odontal and/or periodontal component | 98.13% | DL |
| 7 | tuberculosis, bovine | 98.10% | DL |
| 8 | isolated genetic hair shaft abnormality | 98.08% | DL |
| 9 | tuberculosis, avian | 98.04% | DL |
| 10 | tuberculoma | 98.04% | DL |
| 11 | tuberculous ascites | 98.04% | DL |
| 12 | inactive tuberculosis | 98.04% | DL |
| 13 | hypertrichosis (disease) | 98.00% | DL |
| 14 | esophageal candidiasis | 97.66% | DL |
| 15 | coenurosis | 97.64% | DL |
| 16 | trichosporonosis | 97.59% | DL |
| 17 | hyalohyphomycosis | 97.59% | DL |
| 18 | penicilliosis | 97.59% | DL |
| 19 | geotrichosis | 97.59% | DL |
| 20 | maple bark strippers’ lung | 97.58% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.